Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease
Phosphodiesterase 10A (PDE10A), the enzyme which catalyzes hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is located almost exclusively in striatal γ-amino-butyric acid (GABA)ergic medium spiny neurons (MSNs). Since dopaminergic deficiency in Parkinson...
Gespeichert in:
Veröffentlicht in: | European journal of pharmacology 2021-11, Vol.910, p.174460-174460, Article 174460 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 174460 |
---|---|
container_issue | |
container_start_page | 174460 |
container_title | European journal of pharmacology |
container_volume | 910 |
creator | Lenda, Tomasz Ossowska, Krystyna Berghauzen-Maciejewska, Klemencja Matłoka, Mikołaj Pieczykolan, Jerzy Wieczorek, Maciej Konieczny, Jolanta |
description | Phosphodiesterase 10A (PDE10A), the enzyme which catalyzes hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is located almost exclusively in striatal γ-amino-butyric acid (GABA)ergic medium spiny neurons (MSNs). Since dopaminergic deficiency in Parkinson's disease (PD) leads to functional imbalance of striatal direct and indirect output pathways formed by MSNs, PDE10A seems to be of special interest as a potential therapeutic target in PD.
The aim of the present study was to examine the influence of 7-{5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl}-2-phenylimidazo[1,2-a]pyrimidine (CPL500036), a novel selective inhibitor of PDE10A, on sensorimotor deficits and therapeutic effects of L-3,4-dihydroxyphenylalanine (L-DOPA) in hemiparkinsonian rats.
Animals were unilaterally lesioned with 6-hydroxydopamine, and their sensorimotor deficits were examined in the stepping, cylinder, vibrissae and catalepsy tests. CPL500036 (0.1 and 0.3 mg/kg) was administered either acutely or chronically (2 weeks), alone or in combination with L-DOPA/benserazide (6 mg/kg/6 mg/kg).
Acute treatment with CPL500036 reversed the lesion-induced impairments of contralateral forelimb use in the stepping and cylinder tests but did not influence deficits in the vibrissae test and the lesion-induced catalepsy. Moreover, CPL500036 did not diminish the therapeutic effects produced by acute and chronic treatment with L-DOPA in these tests.
The present study suggests a potential use of CPL500036 as a co-treatment to L-DOPA in PD therapy.
•Unilateral 6-OHDA lesion induced sensorimotor impairment and catalepsy in rats.•CPL500036, a PDE10A inhibitor, reduced sensorimotor deficits in 6-OHDA-lesioned rats.•Acute and chronic CPL500036 did not reduce effects of L-DOPA in sensorimotor tests.•Chronic CPL500036 treatment did not decrease L-DOPA-induced contralateral rotation. |
doi_str_mv | 10.1016/j.ejphar.2021.174460 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2568609257</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299921006142</els_id><sourcerecordid>2568609257</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-f7c104fb23f59afac7ccf662a250ce98d1f07123967bf3436600c5b8cb63eb9b3</originalsourceid><addsrcrecordid>eNp9kcFu3CAURVHVKJmm-YOqYtcu4ukD29hsKo1GbRpppGbRrhHGDw0TD7jgGan_kQ8ulpMus0BIcO67cC8hHxisGTDx5bDGw7jXcc2BszVrqkrAG7JibSMLaBh_S1YArCq4lPKKvEvpAAC15PUluSozLJtarMjTxk9u1PHR-RS8074Y3CNStBbNlGiwdPuwq7OyFLdUUx_OONCEQ751Z6TO713nphBnctyHlFfvME0YdULKYHObGTrtkZ68G_R8PtCoJ3oMfZ6UVQ8v5p8S7V3CrHtPLqweEt4879fk9_dvv7Y_it3Pu_vtZleYCtqpsI1hUNmOl7aW2mrTGGOF4JrXYFC2PbNzEKUUTWfLqhQCwNRdazpRYie78pp8XuaOMfw55Vero0sGh0F7DKekeC1aATmyJqPVgpoYUopo1RjdUce_ioGa-1AHtfSh5j7U0keWfXx2OHVH7P-LXgrIwNcFwPzPs8OoknHoDfYu5oxVH9zrDv8ACgWewg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2568609257</pqid></control><display><type>article</type><title>Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Lenda, Tomasz ; Ossowska, Krystyna ; Berghauzen-Maciejewska, Klemencja ; Matłoka, Mikołaj ; Pieczykolan, Jerzy ; Wieczorek, Maciej ; Konieczny, Jolanta</creator><creatorcontrib>Lenda, Tomasz ; Ossowska, Krystyna ; Berghauzen-Maciejewska, Klemencja ; Matłoka, Mikołaj ; Pieczykolan, Jerzy ; Wieczorek, Maciej ; Konieczny, Jolanta</creatorcontrib><description>Phosphodiesterase 10A (PDE10A), the enzyme which catalyzes hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is located almost exclusively in striatal γ-amino-butyric acid (GABA)ergic medium spiny neurons (MSNs). Since dopaminergic deficiency in Parkinson's disease (PD) leads to functional imbalance of striatal direct and indirect output pathways formed by MSNs, PDE10A seems to be of special interest as a potential therapeutic target in PD.
The aim of the present study was to examine the influence of 7-{5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl}-2-phenylimidazo[1,2-a]pyrimidine (CPL500036), a novel selective inhibitor of PDE10A, on sensorimotor deficits and therapeutic effects of L-3,4-dihydroxyphenylalanine (L-DOPA) in hemiparkinsonian rats.
Animals were unilaterally lesioned with 6-hydroxydopamine, and their sensorimotor deficits were examined in the stepping, cylinder, vibrissae and catalepsy tests. CPL500036 (0.1 and 0.3 mg/kg) was administered either acutely or chronically (2 weeks), alone or in combination with L-DOPA/benserazide (6 mg/kg/6 mg/kg).
Acute treatment with CPL500036 reversed the lesion-induced impairments of contralateral forelimb use in the stepping and cylinder tests but did not influence deficits in the vibrissae test and the lesion-induced catalepsy. Moreover, CPL500036 did not diminish the therapeutic effects produced by acute and chronic treatment with L-DOPA in these tests.
The present study suggests a potential use of CPL500036 as a co-treatment to L-DOPA in PD therapy.
•Unilateral 6-OHDA lesion induced sensorimotor impairment and catalepsy in rats.•CPL500036, a PDE10A inhibitor, reduced sensorimotor deficits in 6-OHDA-lesioned rats.•Acute and chronic CPL500036 did not reduce effects of L-DOPA in sensorimotor tests.•Chronic CPL500036 treatment did not decrease L-DOPA-induced contralateral rotation.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2021.174460</identifier><identifier>PMID: 34469756</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antiparkinson Agents - pharmacology ; Antiparkinson Agents - therapeutic use ; Disease Models, Animal ; GABAergic Neurons - drug effects ; Humans ; L-DOPA ; Levodopa - pharmacology ; Levodopa - therapeutic use ; Male ; Oxidopamine - administration & dosage ; Oxidopamine - toxicity ; Parkinson Disease, Secondary - chemically induced ; Parkinson Disease, Secondary - diagnosis ; Parkinson Disease, Secondary - drug therapy ; Parkinson Disease, Secondary - pathology ; Parkinson's disease ; PDE10A inhibitor ; Phosphodiesterase Inhibitors - pharmacology ; Phosphodiesterase Inhibitors - therapeutic use ; Phosphoric Diester Hydrolases - metabolism ; Rats ; Rotation ; Sensorimotor deficits ; Severity of Illness Index ; Unilateral rat model</subject><ispartof>European journal of pharmacology, 2021-11, Vol.910, p.174460-174460, Article 174460</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-f7c104fb23f59afac7ccf662a250ce98d1f07123967bf3436600c5b8cb63eb9b3</citedby><cites>FETCH-LOGICAL-c408t-f7c104fb23f59afac7ccf662a250ce98d1f07123967bf3436600c5b8cb63eb9b3</cites><orcidid>0000-0002-4800-6511 ; 0000-0001-5011-1620</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejphar.2021.174460$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34469756$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lenda, Tomasz</creatorcontrib><creatorcontrib>Ossowska, Krystyna</creatorcontrib><creatorcontrib>Berghauzen-Maciejewska, Klemencja</creatorcontrib><creatorcontrib>Matłoka, Mikołaj</creatorcontrib><creatorcontrib>Pieczykolan, Jerzy</creatorcontrib><creatorcontrib>Wieczorek, Maciej</creatorcontrib><creatorcontrib>Konieczny, Jolanta</creatorcontrib><title>Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Phosphodiesterase 10A (PDE10A), the enzyme which catalyzes hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is located almost exclusively in striatal γ-amino-butyric acid (GABA)ergic medium spiny neurons (MSNs). Since dopaminergic deficiency in Parkinson's disease (PD) leads to functional imbalance of striatal direct and indirect output pathways formed by MSNs, PDE10A seems to be of special interest as a potential therapeutic target in PD.
The aim of the present study was to examine the influence of 7-{5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl}-2-phenylimidazo[1,2-a]pyrimidine (CPL500036), a novel selective inhibitor of PDE10A, on sensorimotor deficits and therapeutic effects of L-3,4-dihydroxyphenylalanine (L-DOPA) in hemiparkinsonian rats.
Animals were unilaterally lesioned with 6-hydroxydopamine, and their sensorimotor deficits were examined in the stepping, cylinder, vibrissae and catalepsy tests. CPL500036 (0.1 and 0.3 mg/kg) was administered either acutely or chronically (2 weeks), alone or in combination with L-DOPA/benserazide (6 mg/kg/6 mg/kg).
Acute treatment with CPL500036 reversed the lesion-induced impairments of contralateral forelimb use in the stepping and cylinder tests but did not influence deficits in the vibrissae test and the lesion-induced catalepsy. Moreover, CPL500036 did not diminish the therapeutic effects produced by acute and chronic treatment with L-DOPA in these tests.
The present study suggests a potential use of CPL500036 as a co-treatment to L-DOPA in PD therapy.
•Unilateral 6-OHDA lesion induced sensorimotor impairment and catalepsy in rats.•CPL500036, a PDE10A inhibitor, reduced sensorimotor deficits in 6-OHDA-lesioned rats.•Acute and chronic CPL500036 did not reduce effects of L-DOPA in sensorimotor tests.•Chronic CPL500036 treatment did not decrease L-DOPA-induced contralateral rotation.</description><subject>Animals</subject><subject>Antiparkinson Agents - pharmacology</subject><subject>Antiparkinson Agents - therapeutic use</subject><subject>Disease Models, Animal</subject><subject>GABAergic Neurons - drug effects</subject><subject>Humans</subject><subject>L-DOPA</subject><subject>Levodopa - pharmacology</subject><subject>Levodopa - therapeutic use</subject><subject>Male</subject><subject>Oxidopamine - administration & dosage</subject><subject>Oxidopamine - toxicity</subject><subject>Parkinson Disease, Secondary - chemically induced</subject><subject>Parkinson Disease, Secondary - diagnosis</subject><subject>Parkinson Disease, Secondary - drug therapy</subject><subject>Parkinson Disease, Secondary - pathology</subject><subject>Parkinson's disease</subject><subject>PDE10A inhibitor</subject><subject>Phosphodiesterase Inhibitors - pharmacology</subject><subject>Phosphodiesterase Inhibitors - therapeutic use</subject><subject>Phosphoric Diester Hydrolases - metabolism</subject><subject>Rats</subject><subject>Rotation</subject><subject>Sensorimotor deficits</subject><subject>Severity of Illness Index</subject><subject>Unilateral rat model</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu3CAURVHVKJmm-YOqYtcu4ukD29hsKo1GbRpppGbRrhHGDw0TD7jgGan_kQ8ulpMus0BIcO67cC8hHxisGTDx5bDGw7jXcc2BszVrqkrAG7JibSMLaBh_S1YArCq4lPKKvEvpAAC15PUluSozLJtarMjTxk9u1PHR-RS8074Y3CNStBbNlGiwdPuwq7OyFLdUUx_OONCEQ751Z6TO713nphBnctyHlFfvME0YdULKYHObGTrtkZ68G_R8PtCoJ3oMfZ6UVQ8v5p8S7V3CrHtPLqweEt4879fk9_dvv7Y_it3Pu_vtZleYCtqpsI1hUNmOl7aW2mrTGGOF4JrXYFC2PbNzEKUUTWfLqhQCwNRdazpRYie78pp8XuaOMfw55Vero0sGh0F7DKekeC1aATmyJqPVgpoYUopo1RjdUce_ioGa-1AHtfSh5j7U0keWfXx2OHVH7P-LXgrIwNcFwPzPs8OoknHoDfYu5oxVH9zrDv8ACgWewg</recordid><startdate>20211105</startdate><enddate>20211105</enddate><creator>Lenda, Tomasz</creator><creator>Ossowska, Krystyna</creator><creator>Berghauzen-Maciejewska, Klemencja</creator><creator>Matłoka, Mikołaj</creator><creator>Pieczykolan, Jerzy</creator><creator>Wieczorek, Maciej</creator><creator>Konieczny, Jolanta</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4800-6511</orcidid><orcidid>https://orcid.org/0000-0001-5011-1620</orcidid></search><sort><creationdate>20211105</creationdate><title>Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease</title><author>Lenda, Tomasz ; Ossowska, Krystyna ; Berghauzen-Maciejewska, Klemencja ; Matłoka, Mikołaj ; Pieczykolan, Jerzy ; Wieczorek, Maciej ; Konieczny, Jolanta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-f7c104fb23f59afac7ccf662a250ce98d1f07123967bf3436600c5b8cb63eb9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Antiparkinson Agents - pharmacology</topic><topic>Antiparkinson Agents - therapeutic use</topic><topic>Disease Models, Animal</topic><topic>GABAergic Neurons - drug effects</topic><topic>Humans</topic><topic>L-DOPA</topic><topic>Levodopa - pharmacology</topic><topic>Levodopa - therapeutic use</topic><topic>Male</topic><topic>Oxidopamine - administration & dosage</topic><topic>Oxidopamine - toxicity</topic><topic>Parkinson Disease, Secondary - chemically induced</topic><topic>Parkinson Disease, Secondary - diagnosis</topic><topic>Parkinson Disease, Secondary - drug therapy</topic><topic>Parkinson Disease, Secondary - pathology</topic><topic>Parkinson's disease</topic><topic>PDE10A inhibitor</topic><topic>Phosphodiesterase Inhibitors - pharmacology</topic><topic>Phosphodiesterase Inhibitors - therapeutic use</topic><topic>Phosphoric Diester Hydrolases - metabolism</topic><topic>Rats</topic><topic>Rotation</topic><topic>Sensorimotor deficits</topic><topic>Severity of Illness Index</topic><topic>Unilateral rat model</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lenda, Tomasz</creatorcontrib><creatorcontrib>Ossowska, Krystyna</creatorcontrib><creatorcontrib>Berghauzen-Maciejewska, Klemencja</creatorcontrib><creatorcontrib>Matłoka, Mikołaj</creatorcontrib><creatorcontrib>Pieczykolan, Jerzy</creatorcontrib><creatorcontrib>Wieczorek, Maciej</creatorcontrib><creatorcontrib>Konieczny, Jolanta</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lenda, Tomasz</au><au>Ossowska, Krystyna</au><au>Berghauzen-Maciejewska, Klemencja</au><au>Matłoka, Mikołaj</au><au>Pieczykolan, Jerzy</au><au>Wieczorek, Maciej</au><au>Konieczny, Jolanta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2021-11-05</date><risdate>2021</risdate><volume>910</volume><spage>174460</spage><epage>174460</epage><pages>174460-174460</pages><artnum>174460</artnum><issn>0014-2999</issn><eissn>1879-0712</eissn><abstract>Phosphodiesterase 10A (PDE10A), the enzyme which catalyzes hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is located almost exclusively in striatal γ-amino-butyric acid (GABA)ergic medium spiny neurons (MSNs). Since dopaminergic deficiency in Parkinson's disease (PD) leads to functional imbalance of striatal direct and indirect output pathways formed by MSNs, PDE10A seems to be of special interest as a potential therapeutic target in PD.
The aim of the present study was to examine the influence of 7-{5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl}-2-phenylimidazo[1,2-a]pyrimidine (CPL500036), a novel selective inhibitor of PDE10A, on sensorimotor deficits and therapeutic effects of L-3,4-dihydroxyphenylalanine (L-DOPA) in hemiparkinsonian rats.
Animals were unilaterally lesioned with 6-hydroxydopamine, and their sensorimotor deficits were examined in the stepping, cylinder, vibrissae and catalepsy tests. CPL500036 (0.1 and 0.3 mg/kg) was administered either acutely or chronically (2 weeks), alone or in combination with L-DOPA/benserazide (6 mg/kg/6 mg/kg).
Acute treatment with CPL500036 reversed the lesion-induced impairments of contralateral forelimb use in the stepping and cylinder tests but did not influence deficits in the vibrissae test and the lesion-induced catalepsy. Moreover, CPL500036 did not diminish the therapeutic effects produced by acute and chronic treatment with L-DOPA in these tests.
The present study suggests a potential use of CPL500036 as a co-treatment to L-DOPA in PD therapy.
•Unilateral 6-OHDA lesion induced sensorimotor impairment and catalepsy in rats.•CPL500036, a PDE10A inhibitor, reduced sensorimotor deficits in 6-OHDA-lesioned rats.•Acute and chronic CPL500036 did not reduce effects of L-DOPA in sensorimotor tests.•Chronic CPL500036 treatment did not decrease L-DOPA-induced contralateral rotation.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34469756</pmid><doi>10.1016/j.ejphar.2021.174460</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-4800-6511</orcidid><orcidid>https://orcid.org/0000-0001-5011-1620</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2999 |
ispartof | European journal of pharmacology, 2021-11, Vol.910, p.174460-174460, Article 174460 |
issn | 0014-2999 1879-0712 |
language | eng |
recordid | cdi_proquest_miscellaneous_2568609257 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Animals Antiparkinson Agents - pharmacology Antiparkinson Agents - therapeutic use Disease Models, Animal GABAergic Neurons - drug effects Humans L-DOPA Levodopa - pharmacology Levodopa - therapeutic use Male Oxidopamine - administration & dosage Oxidopamine - toxicity Parkinson Disease, Secondary - chemically induced Parkinson Disease, Secondary - diagnosis Parkinson Disease, Secondary - drug therapy Parkinson Disease, Secondary - pathology Parkinson's disease PDE10A inhibitor Phosphodiesterase Inhibitors - pharmacology Phosphodiesterase Inhibitors - therapeutic use Phosphoric Diester Hydrolases - metabolism Rats Rotation Sensorimotor deficits Severity of Illness Index Unilateral rat model |
title | Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T07%3A07%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiparkinsonian-like%20effects%20of%20CPL500036,%20a%20novel%20selective%20inhibitor%20of%20phosphodiesterase%2010A,%20in%20the%20unilateral%20rat%20model%20of%20Parkinson's%20disease&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Lenda,%20Tomasz&rft.date=2021-11-05&rft.volume=910&rft.spage=174460&rft.epage=174460&rft.pages=174460-174460&rft.artnum=174460&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2021.174460&rft_dat=%3Cproquest_cross%3E2568609257%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2568609257&rft_id=info:pmid/34469756&rft_els_id=S0014299921006142&rfr_iscdi=true |